Opioids are widely used as
analgesics in clinical
pain management for decades. However,
opioid tolerance is a serious problem which limits their usefulness. The mechanisms of
opioid tolerance are complex which involve many regulatory factors.
Glutamate is an important extracellular
neurotransmitter which activates
glutamate receptor and induces a series of signal transduction to regulate the development of
opioid tolerance. Previous studies have indicated an involvement of
NMDA receptors in the development of beta-
opioid tolerance and associated abnormal
pain sensitivity. Many
NMDA receptor antagonists had been demonstrated to regulate
morphine tolerance development. In the
NMDA-mediated intracellular mechanisms of
opioid tolerance,
protein kinase C (PKC) modulates beta-
opioid receptor activation. Besides, the
opioid receptor desensitization involves phosphorylation of receptors and subsequent binds to
beta-arrestin. In knockout mice, lacking beta-arrestin-2, desensitization of beta-
opioid receptor did not occur after chronic
morphine treatment, and these animals also failed to develop antinociceptive tolerance. Moreover,
morphine tolerance can be completely reversed with a low dose of the classical PKC inhibitor
chelerythrine in the beta-arrestin-2 knock-out, but not wild-type mice. These findings indicate that, in the absence of beta-arrestin-2, contributions of PKC-dependent regulatory system would become apparent. In summary, PKC is regulated by
NMDA receptors to affect the development of
opioid tolerance, beta-arrestin-2 also influences PKC-induced
opioid receptor desensitization. PKC may play an important role to coordinate these factors which regulate
opioid tolerance.